The effect of intravenous iron therapy and erythropoesis-stimulation agent combination on renal transplant outcomes

Not Applicable

Recruiting

• Conditions: Diseases of the genitourinary system

• Registration Number: KCT0008143
• Lead Sponsor: Yonsei University Health System, Severance Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 302

Inclusion Criteria

1. living donor transplantation (Age >19)
2. Ferririn<700?/L, TSAT<40%

Exclusion Criteria

1. subject who is CDC(+), FXM(+)
2. Subject with a active infection
3. Hematologic malignancy, monoclonal gammaglobulin Dz, Hematologic Dz induced anemia
4. Receiving treatment of malignant tumor
5. Subject who is HIV(+)
6. Recent(within 3 months) participation in an interventional trial
7. ALT, AST >3 times upper limit of normal

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of the number of blood transfusions according to the combination of intravenous iron therapy and EPO agent on perioperative period

Secondary Outcome Measures

Name	Time	Method
comparison of changes in anemia parameters(ferritin, TSAT, EPO level) following the administraiton of intravenous iron therapy and EPO agent;comparison of changes in hepcidin expression level following the administraiton of intravenous iron therapy and EPO agent;comparison of changes in oxidative stress marker following the administraiton of intravenous iron therapy and EPO agent;comparison of changes in immunologic parameters(de novo DSA, antibody-mediated rejection rate, death censored graft survivial and patient survival rate) following the administraiton of intravenous iron therapy and EPO agent